The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy

详细信息    查看全文

• 作者：Lu-Ning Zhang ; Weiwei Xiao ; Pu-Yun OuYang ; Kaiyun You ; Zhi-Fan Zeng…
• 关键词：Monocyte count ; Prognosis ; Pathological T3N0M0 ; Rectal cancer
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：36
• 期：10
• 页码：8213-8219
• 全文大小：344 KB
• 参考文献：1.Rodel C, Hofheinz R, Liersch T. Rectal cancer: state of the art in 2012. Curr Opin Oncol. 2012;24:441-.CrossRef PubMed
  2.McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12, Cd008368.PubMed
  3.Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-0.CrossRef PubMed
  4.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-4.CrossRef PubMed
  5.Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-b-cell lymphoma. Leukemia. 2011;25:1502-.CrossRef PubMed
  6.Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 2006;139:755-4.CrossRef PubMed
  7.Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with scc-ag level. Gynecol Oncol. 2012;124:92-.CrossRef PubMed
  8.Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273-.PubMed Central CrossRef PubMed
  9.Kumagai S, Marumo S, Shoji T, Sakuramoto M, Hirai T, Nishimura T, et al. Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 2014;85:457-4.CrossRef
  10.Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. J Proteome. 2009;72:918-7.CrossRef
  11.Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777-9.CrossRef PubMed
  12.Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-4.CrossRef PubMed
  13.Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-9.PubMed Central CrossRef PubMed
  14.Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science. 1983;220:210-.CrossRef PubMed
  15.Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315-2.CrossRef PubMed
  16.Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-.PubMed Central CrossRef PubMed
  17.Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357:539-5.CrossRef PubMed
  18.Coussens LM, Tinkle CL, Hanahan D, Werb Z. Mmp-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481-0.PubMed Central CrossRef PubMed
  19.Locati M, Deuschle U, Massardi ML, Martinez FO, Sironi M, Sozzani S, et al. Analysis of the gene expression profile activated by the cc chemokine ligand 5/rantes and by lipopolysaccharide in human monocytes. J Immunol. 2002;168:3557-2.CrossRef PubMed
  20.Lewis CE, Leek R, Harris A, McGee JO. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol. 1995;57:747-1.PubMed
  21.Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol. 2011;41:2522-.CrossRef PubMed
  22.Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267:204-5.CrossRef PubMed
  23.Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540-0.CrossRef PubMed
  24.Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-5.CrossRef PubMed
  25.Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with vegf expression and microvessel density. Oncol Rep. 2005;14:425-1.PubMed
  26.Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-.CrossRef PubMed
  
• 作者单位：Lu-Ning Zhang (1)
  Weiwei Xiao (1)
  Pu-Yun OuYang (1)
  Kaiyun You (4)
  Zhi-Fan Zeng (1)
  Pei-Rong Ding (2)
  Zhi-Zhong Pan (2)
  Rui-Hua Xu (3)
  Yuan-Hong Gao (1)
  
  1. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, China
  4. Department of Oncology, The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  2. Department of Colorectal Surgery, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
  3. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

It remains controversial whether adjuvant therapy should be delivered to pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy. Thus identification of patients at high risk is of particular importance. Herein, we aimed to evaluate whether the absolute peripheral blood monocyte count can stratify the pathological T3N0M0M0 rectal cancer patients in survival. A total of 270 pathological T3N0M0 rectal cancer patients with total mesorectal excision-principle radical resection were included. The optimal cut-off value of preoperative monocyte count was determined by receiver operating characteristic curve analysis. Overall survival and disease-free survival between low- and high-monocyte were estimated by Kaplan–Meier method and Cox regression model. The optimal cut-off value for monocyte count was 595 mm3. In univariate analysis, patients with monocyte counts higher than 595/mm3 had significantly inferior 5-year overall survival (79.2 vs 94.2 %, P--.006) and disease-free survival (67.8 vs 86.0 %, P-lt;-.001). With adjustment for the known covariates, monocyte count remained to be associated with poor overall survival (HR--.55, 95 % CI 1.27-.10; P--.008) and disease-free survival (HR--.63, 95 % CI 1.48-.69; P--.001). Additionally, the significant association of monocyte count with disease-free survival was hardly influenced in the subgroup analysis, whereas this correlation was restricted to the males and patients with normal carcinoembryonic antigen (CEA) level (<5 μg/L), tumor grade II, and with adjuvant therapy. High preoperative monocyte count is independently predictive of worse survival of pathological T3N0M0 rectal cancer patients without neoadjuvant chemoradiotherapy. Postoperative adjuvant therapy might be considered for patients with high-monocyte count. Keywords Monocyte count Prognosis Pathological T3N0M0 Rectal cancer